Teva submits XM02 BLA with US FDA to treat chemotherapy-induced neutropenia
Teva Pharmaceutical Industries Ltd, announced the submission of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulati...
PharmaBiz,
Wed Dec 02 23:51:25 PST 2009
• Found on Yahoo! News
Carfilzomib Data Demonstrate Promising Efficacy and Tolerability Signals in Ongoin...
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
redOrbit,
Mon Dec 07 08:09:15 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
Carfilzomib Demonstrates Encouraging Response Rates in Patients with Relapsed and/...
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead ...
redOrbit,
Mon Dec 07 08:08:10 PST 2009
• Found on Yahoo! News
New research demonstrates advances in optimizing treatments and quality of life
Research presented today at the 51st Annual Meeting of the American Society of Hematology explores optimal induction therapies for managing multiple myeloma, the importance of advance care ...
EurekAlert!,
Mon Dec 07 06:28:00 PST 2009
• Found on Yahoo! News
Advances in diagnosing and treating leukemia and myeloproliferative disorders
Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces po...
EurekAlert!,
Mon Dec 07 06:27:50 PST 2009
• Found on Yahoo! News
Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival ...
Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive Nhl D
redOrbit,
Mon Dec 07 05:07:50 PST 2009
• Found on Yahoo! News
BUSINESS WIRE: Phase II Data Evaluating REVLIMID^® + Rituximab in Relapsed Patient...
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
vwd.de,
Mon Dec 07 07:23:03 PST 2009
• Found on Yahoo! News
Phase II Data Evaluating REVLIMID® + Rituximab in Relapsed Patients with Chronic L...
BOUDRY, Switzerland----Celgene International Sàrl announced that data evaluating combination therapy with REVLIMID and rituximab in patients with relapsed chronic lymphocytic leukaemia were...
Business Wire via Yahoo! Finance,
Mon Dec 07 07:12:00 PST 2009
• Found on Yahoo! News
VELCADE® (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Su...
NEW ORLEANS----Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the tre...
Business Wire via Yahoo! Finance,
Mon Dec 07 05:47:00 PST 2009
• Found on Yahoo! News
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marq...
SOUTH SAN FRANCISCO, Calif. -- Hana Biosciences , a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced data from its pivotal Phase 2 rALLy cli...
GlobeNewswire via Yahoo! Finance,
Mon Dec 07 08:01:00 PST 2009
• Found on Yahoo! News
Allos Therapeutics' FOLOTYN Demonstrates Activity in Patients with Relapsed or Ref...
NEW ORLEANS & WESTMINSTER, Colo.----Allos Therapeutics, Inc. today reported a new analysis of data from the Company
Business Wire via Yahoo! Finance,
Mon Dec 07 07:00:00 PST 2009
• Found on Yahoo! News
Significant potential of late- and mid-stage Novartis hematology portfolio to be s...
Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------...
OnVista,
Sun Dec 06 19:38:14 PST 2009
• Found on Yahoo! News
Updated results from pivotal phase III EXTEND clinical trial of pixantrone announc...
Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH")...
News-Medical-Net,
Sun Dec 06 23:45:21 PST 2009
• Found on Yahoo! News
Carfilzomib Data Demonstrate Promising Efficacy and Tolerability Signals in Ongoin...
Onyx Pharmaceuticals, Inc. today announced interim results from the Phase 1b/2 006 study, demonstrating that carfilzomib, when administered with the standard therapies lenalidomide and low ...
PR Newswire via Yahoo! Finance,
Mon Dec 07 05:01:00 PST 2009
• Found on Yahoo! News
Researchers explore optimal induction therapies for managing blood cancer
There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to disco...
News-Medical-Net,
Sun Dec 06 22:15:30 PST 2009
• Found on Yahoo! News
Poster summarizing clinical trial data regarding SB-743921 presented by Cytokineti...
Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting an...
News-Medical-Net,
Sun Dec 06 22:15:40 PST 2009
• Found on Yahoo! News
Updated safety data from pivotal Phase 2b 003-A1 study of carfilzomib announced
Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pr...
News-Medical-Net,
Sun Dec 06 21:15:40 PST 2009
• Found on Yahoo! News
Positive final data from Phase 2 study of ISTODAX presented
Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the Nation...
News-Medical-Net,
Sun Dec 06 21:00:30 PST 2009
• Found on Yahoo! News
Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival ...
Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology Annual Meeting ...
PR Newswire via Yahoo! Finance,
Sun Dec 06 22:30:00 PST 2009
• Found on Yahoo! News